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ABSTRACT 
The standard treatment of primary hypoparathyroidism with oral calcium supplementation and 
calcitriol (or an analog), intended to control hypocalcemia and hyperphosphatemia and avoid 
hypercalciuria, remains challenging for both patients and clinicians. In 2015 human PTH(1-84) 
administered as a daily subcutaneous injection was approved as an adjunctive treatment in 
patients who cannot be well controlled on the standard treatments alone.  
This open-label study aimed to assess the safety and efficacy of an oral human PTH(1–34) 
formulation as an adjunct to standard treatment in adult subjects with hypoparathyroidism. Oral 
hPTH(1-34) tablets (0.75 mg human hPTH(1-34) acetate) were administered four times daily, for 
16 consecutive weeks and changes in calcium supplementation and alfacalcidol use, albumin-
adjusted serum calcium (ACa), serum phosphate, urinary calcium excretion and quality of life 
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throughout the study were monitored. Of the 19 enrolled subjects, 15 completed the trial per 
protocol. A median 42% reduction from baseline in exogenous calcium dose was recorded 
(p=0.001), while median serum ACa levels remained above the lower target ACa levels for 
HypoPT patients (>7.5 mg/dL) throughout the study. Median serum phosphate levels rapidly 
decreased (23%; p=0.0003) 2-hours following the first dose and were maintained within the 
normal range for the duration of the study. A notable, but not statistically significant, median 
decrease (21%; p= 0.07) in 24-hour urine calcium excretion was observed between the first and 
last treatment days. Only four possible drug-related, non-serious adverse events were reported 
over the 16-week study, all by the same patient. A small but statistically significant increase 
from baseline quality of life (5%, p=0.03) was reported by the end of the treatment period.  
Oral hPTH(1-34) treatment was generally safe and well tolerated and allowed for a reduction in 
exogenous calcium supplementation, while maintaining normocalcemia in adult patients with 
hypoparathyroidism.  
Keywords: ORAL PARATHYROID HORMONE, HYPOPARATHYROIDISM, 
PARATHYROID‐RELATED DISORDERS; CALCIUM/PHOSPHATE DISORDERS; 
PARATHYROID HORMONE  
INTRODUCTION 
Primary Hypoparathyroidism (HypoPT) is a rare mineral metabolism disorder, with a prevalence 
of 22 per 100,000 individuals (1), and is biochemically characterized by low serum calcium and 
low or undetectable parathyroid hormone (PTH) levels. The leading cause of HypoPT in adults is 
iatrogenic, typically secondary to excision or injury incurred during anterior neck surgery (2).  
Less common etiologies include autoimmune disease, congenital absence, and genetic disorders 
resulting in defective biosynthesis or secretion of the hormone (3). The characteristic 
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hypocalcemia in HypoPT is due to PTH levels insufficient to adequately mobilize calcium from 
bone, reabsorb filtered calcium from the distal nephron, or increase intestinal calcium absorption 
by stimulating renal 25-hydroxyvitamin D 1α-hydroxylase activity and subsequent 1,25-
dihydroxyvitamin D (1,25(OH)2D) synthesis. Hyperphosphatemia develops due to the loss of  
the phosphaturic effect of PTH (4).  
The standard treatment of HypoPT with oral calcium supplementation and calcitriol (or an 
analog), intended to control hypocalcemia and hyperphosphatemia and avoid hypercalciuria, 
remains challenging for both patients and clinicians. Loss of renal PTH action decreases renal 
tubular reabsorption of calcium and excretion of phosphate causing hypercalciuria and 
hyperphosphatemia respectively (5). Thus, patients with chronic hypoparathyroidism have been 
found to have an increased risk of renal complications, such as nephrocalcinosis, nephrolithiasis, 
renal insufficiency and often ectopic calcification in other organs. Titration of calcium and 
calcitriol dose is often slow and imprecise and may require frequent dose adjustments. In 
addition, the intake of supplements multiple times throughout the day is inconvenient and often 
causes gastrointestinal intolerance (6). PTH deficiency leads to low bone turnover and markedly 
altered microarchitectural and biomechanical properties of the skeleton that result in structural 
and dynamic skeletal defects which are not addressed by calcium supplements and active vitamin 
D therapy (7, 8). Standard treatment is titrated to achieve blood calcium levels that are at the lower 
limit of normal to reduce the risk of hypercalciuria and ectopic calcification (9). Patients have 
repeatedly reported quality of life problems such as altered mood and cognition, which may be 
caused by the relatively low blood calcium provided by standard treatment (10-12). Replacement 
therapy with PTH has the potential advantages of reducing the high dose of calcium 
supplements, providing better correction of hypocalcemia and hyperphosphatemia, and 
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decreasing urine calcium. With these potential advantages, treatment of PTH deficiency with 
PTH is compelling. 
In 2015, the US Food and Drug Administration approved a daily subcutaneous injection of the 
full-length human PTH molecule (hPTH (1-84)), synthesized through recombinant technology as 
an adjunct to calcium and calcitriol (or other calcitriol analogs) treatment in order to control 
hypocalcemia and hyperphosphatemia in patients with HypoPT. Currently, two human PTH 
(hPTH) analogs are clinically available for different indications: hPTH(1–34), the 1–34 
N-terminal fragment of human PTH (teriparatide) for the treatment of osteoporosis, and 
hPTH(1–84) for HypoPT. Both the full length 84 amino acid hormone (13-16) and its fully active 
amino-terminal 34 amino acid peptide (17-24) have demonstrated salutary effects in HypoPT 
management and have lowered or eliminated supplemental calcium and active vitamin D 
requirements while maintaining serum calcium within the reference range. Presently, both 
hPTH(1-84) and hPTH(1-34) are only available in injectable subcutaneous forms, and while 
hPTH(1-84) is approved for the treatment of hypoparathyroidism, hPTH(1-34) is only approved 
for the treatment of osteoporosis. An oral formulation devoid of the injection-related 
complexities will likely have a positive impact on compliance and adherence, simplifying the 
patients’ treatment regimen and their general quality of life. 
Entera Bio is developing an oral formulation of hPTH(1-34) based on its novel drug delivery 
technology that facilitates absorption of proteins, which has achieved therapeutic relevant plasma 
concentrations and pharmacokinetics of the drug (23).  We report the results of a 16-week pilot 
study aimed to assess the safety, tolerability (rate of discontinuation), and efficacy (reduction of 
calcium supplementation) of an oral hPTH(1–34) formulation as an add-on therapy to 
conventional treatment in adults with HypoPT.  
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MATERIALS AND METHODS 
Study drug 
Oral hPTH(1-34) tested in the current study is based on the proprietary oral peptide delivery 
technology of Entera Bio Ltd.(24). The technology consists of the novel excipients salcaprozate 
sodium and soybean trypsin inhibitor (SBTI), which facilitate absorption of the hPTH(1-34) 
peptide across the GI wall and protect the hPTH(1-34) peptide from proteolysis. Each tablet 
contained 0.75 mg hPTH(1-34) acetate, equivalent to 0.69 mg of the hPTH active moiety 
(formulation code EBP02). Tablets were provided by Entera Bio Ltd., Jerusalem, Israel.  
Study design 
The study was an open-label, multicenter pilot study, conducted in Israel between August 12, 
2014 and June 21, 2015, in which Oral hPTH(1-34) was administered four times daily for 16 
consecutive weeks for the treatment of hypocalcemia in patients with HypoPT. The study was 
conducted in accordance with the Good Clinical Practice Guidelines and the Declaration of 
Helsinki and registered in the US clinical trials database (Clinical trial # - NCT02152228). The 
Institutional Review Boards at each investigational site approved the protocol before study 
initiation. Written informed consent was obtained from patients before participation in the study.  
The main inclusion criteria included males and females aged 18-80 years, body mass index 
(BMI) 18–30 kg/m2, with HypoPT for more than 12 months, who, at the time of enrollment, 
were taking supplemental calcium with ≥1.0 g elemental calcium/day with correlate calcitriol 
analog dose and had 25-hydroxyvitamin D [25(OH)D] levels ≥ 20 ng/mL. Individuals were 
eligible for the trial after physical, cardiac and renal evaluations, as well as blood chemistry and 
hematology assessments were found to be within reference ranges. Abnormalities due to 
HypoPT, such as low serum calcium or high phosphate, were acceptable. Main exclusion criteria 
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included anemia, renal insufficiency (estimated glomerular filtration rate (eGFR) 
<40mL/min/1.73m2), elevated liver associated enzymes, alcohol or drug abuse, positive serology 
test (HIV, HBsAg, HCV Ab) or active infections, nephrocalcinosis, concurrent drugs that might 
interfere with mineral metabolism, and pregnancy or planned pregnancy. 
Treatment with calcium supplements and calcitriol analogs (generally alfacalcidol) were 
continued as prescribed by the physicians providing long-term care of each patient’s HypoPT. 
On treatment day 1, the subjects underwent a comprehensive evaluation, including physical 
exam, medical history, complete blood count and serum biochemical safety and efficacy 
analysis. Patients were then treated with three in-clinic doses of 0.75 mg Oral hPTH(1-34), 
delivered at four-hour intervals, at approximately 08:00, 12:00 and 16:00. The first dose was 
administered after an overnight fast and meals were supplied one hour post the first and second 
dose administrations. The fourth dose of the first treatment day was self-administered at home, 
after 20:00. Thereafter, the subjects were instructed to self-administer the study drug at home 
with 100 mL water, 4 times a day (prior to breakfast, lunch, dinner and at bedtime) for a 
treatment period of 16 weeks. The study drug was to be taken at least 30 minutes before eating or 
drinking, at least 30 minutes before consumption of calcium tablets or any other drug, and at 
least 1 hour after consumption of any food or drug. During the treatment period, the dose was 
titrated up to a maximum of 12 tablets a day (total daily oral hPTH(1-34) dose: 9 mg) by the 
Investigator, according to each subject's albumin adjusted serum calcium (ACa) and supplement 
treatment regimen. Subjects’ ACa was measured weekly for the first 4 weeks, biweekly for the 
next 8 weeks, and once again at the end of the study. The decision to decrease or increase the 
doses of Oral hPTH(1-34), supplemental calcium, or alfacalcidol was made according to each 
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patients’ pre-dose ACa levels according to dosing guidelines presented in Table 1 and adjusted 
according to the clinical judgment of the investigator. 
Based on previous Phase 1 studies and IRB approval, the maximal allowed dosage was 9.0 mg 
hPTH(1-34) acetate per day. Due to the heterogeneous patient population, their sensitivity to 
PTH, and their variable daily supplements, the extent of the adjustment was left to the 
investigators' discretion for how to best adjust in order to achieve the individual patient’s target 
ACa levels. Follow up visits were performed at the end of weeks 1, 2, 3, 4, 6, 8, 10, 12, 14 and at 
the end of week 16, when treatment with Oral hPTH(1-34) was discontinued. Serum calcium, 
phosphate, albumin, and creatinine levels were evaluated at all visits (before and one-hour after 
self-administration of the study drug at the clinic) and medication dose adjustments were 
performed, according to the subjects’ ACa levels. Individuals were contacted by a study 
coordinator during each week that did not include a clinical visit. Urinalysis and 24hr urine 
collection for calcium, creatinine, and phosphate was performed prior to treatment initiation and 
at the end of weeks 8 and 16. A follow-up/end of study (FU/EOS) visit was performed 7–14 days 
after the completion of the treatment phase or at early trial discontinuation. 
Treatment compliance was monitored throughout the study by checking personal diaries and 
weekly patient status update calls. Compliance to treatment was calculated as the percentage of 
the tablets consumed by the subject from the prescribed amounts and defined as follows: >80% 
(good), 60-80% (satisfactory) and <60% (poor).  
Quality of life (QoL) was assessed with the EQ-5D-5L™ (EuroQoL), a standardized instrument 
used to measure health-related quality of life assessments, which was completed by the subjects 
at each visit during the treatment phase. This instrument used a Visual Analog Scale (VAS, 1 
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being worst to 100 being best) to record patients’ self-rated overall health. This instrument has 
been used to assess quality of life in patients with HypoPT (10).  
Hypocalcemia-related symptoms were reported at each treatment visit, beginning the first visit 
after treatment was initiated. 
Pharmacokinetic and pharmacodynamics tests following first two drug doses  
Blood samples were collected following the two first drug administrations that took place on the 
first study day. To this end, samples were collected prior to and 10, 15, 20, 30, 45, 60, 90, 180, 
and 240 minutes following administration of each of the two doses. Blood samples were 
collected into spray-coated EDTA tubes, placed on ice and spun at 4°C, 2500 g, 10 minutes. The 
separated plasma was stored at -20 ⁰C until analysis. Analysis of hPTH(1-34) in human plasma 
was performed by Bioanalytical Facility, University of East Anglia (UK), using a validated 
commercial chemiluminescence-based immunoassay (IDS-iSYS hPTH(1-34) Boldon, UK) on a 
IDS-iSYS automated analyzer. 
For pharmacodynamic analysis, blood samples collected on the first study visit prior to, 60 and 
180 minutes following the first drug dose, as well as 60, 180 and 240 minutes following the 
second dose, were used to determine serum calcium, albumin and phosphate levels.  
Data analysis 
Pharmacokinetics, pharmacodynamics, and safety analyses included the data of all enrolled 
subjects (N=19), unless noted otherwise, all of whom completed the first study day. Evaluation 
of treatment compliance included all subjects that completed the 16-week trial (N=17). All other 
analyses, including the 16-week calculation of supplemental calcium and alfacalcidol dosing, 
serum ACa and phosphate concentrations, urine calcium excretion, quality of life evaluation, and 
hypocalcemia-related symptoms were performed on data collected from all patients completing 
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the study per protocol (N=15). For the two subjects not treated per protocol, calcium 
supplements were increased during the initial weeks of the study in order to increase ACa levels 
above baseline value instead of having the levels maintained. 
Statistical analysis 
For categorical variables, descriptive statistics included sample size, absolute and relative 
frequency for proportions and 95% confidence interval (if appropriate). For continuous variables, 
descriptive statistics included sample size, arithmetic mean, geometric mean, standard deviation, 
standard error, coefficient of variation (if appropriate), median, minimum and maximum and 
95% confidence interval for means. 
Pharmacokinetic analysis 
The following parameters were derived from a non-compartmental pharmacokinetic analysis by 
SAS Software package (SAS Institute Inc., Cary, NC, USA) using individual hPTH(1-34) 
concentration data: Cmax - maximum plasma concentration, Tmax - time to maximum plasma 
concentration, AUClast - area under the plasma concentration-time curve (AUC) from time of 
administration up to last measurable concentration, calculated by linear trapezoidal summation, 
λz - elimination rate constant, determined by linear regression of the terminal points of the ln - 




Nineteen subjects with confirmed diagnoses of HypoPT for more than 1 year were enrolled in 
the study. Most of the subjects (16/19) were female. The median age of the subjects was 41.1 
years (range 20.3 – 71.0 years), with a median body mass index (BMI) of 25.5 kg/cm2. 
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Seventeen subjects completed the study, while two subjects withdrew on the first day of the 
study - one due to withdrawal of consent and one due to an unrelated serious adverse event 
(SAE) of hypercalcemia, which occurred prior to the first study drug administration and was 
only identified after administration of the first dose, when pre-dose lab results were received.  
Reduction in supplemental calcium and alfacalcidol (or calcitriol) doses: 
The mean daily doses of Oral hPTH(1-34) by week are summarized in Table 3. In accordance 
with the study protocol, supplemental calcium intake was reduced in parallel with the gradual 
increase in the daily Oral hPTH(1-34) dose (up to 9.0 mg) to maintain stable serum ACa 
concentrations. Calcium supplement requirements decreased consistently during the study (Table 
4; Figure 1a) and was significantly lower than baseline from Week 4 until the end of the study. 
Median exogenous calcium doses decreased from 3.6 g at baseline to 2.2 g by week 16, 
equivalent to a 42% (p=0.0001) reduction from baseline requirements. By the end of the study, 
40% of the patients achieved a ≥50% reduction in calcium intake and 73% of patients achieved a 
≥30% reduction. While some decreases in the average alfacalcidol doses were observed 
throughout the study, mean alfacalcidol doses reduced 4.3% from 1.1 to 1.0 µg per day, which 
was not significantly different than baseline doses. Despite significant reductions in 
supplemental calcium doses, total serum ACa levels remained stable and above the lower target 
ACa levels for HypoPT patients (>7.5 mg/ dL(25)) (Figure 1b). At the start of the study, 20% of 
patients had ACa> 8.5 mg/dL, compared to 33% at the end of week 16.  
Human hPTH(1-34) pharmacokinetics following Oral hPTH(1-34) administration  
After administration of the first and the second doses, the respective median maximum plasma 
hPTH(1-34) concentrations were 47.9 pg/mL and 41.2  pg/mL (Table 5), which were reached at 
a median 20.0 min and 30.0 min, respectively, after dosing (Table 5). Similarly, the total 
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systemic exposure (AUClast) was considerably greater after the first dose of Oral hPTH(1-34) 
administered after an overnight fast, in comparison to the second dose (Table 5) administered 
three hours after a standard meal. The mean terminal half-life of hPTH(1-34) was similar after 
both dose administrations (21.1 min and 27.5 min for the first and second doses, respectively). 
Serum ACa and phosphate levels 
Following the first two dose administrations with the starting dose of 0.75mg Oral hPTH(1-34) 
tablets on Day 1, there was no significant effect on serum ACa levels. With that said, an upward 
trend in serum ACa levels was observed three hours post-dose, following a transient decrease at 
one-hour post-dose. As shown in Figure 2, the effect of Oral hPTH(1-34) on serum ACa levels 
extended well beyond the duration of exposure to the drug, resembling an indirect 
pharmacodynamic model (26).  
A more prominent effect was observed for serum phosphate levels, which rapidly decreased 
following the first Oral hPTH(1-34) dose, bringing the high baseline levels to within the 
reference range (2.5 – 4.5 mg/dL).  
The phosphate levels continued to stay low after the second dose, remaining within the reference 
range for a total of at least 7 hours. The same rapid effect on phosphate levels was observed 
throughout the study; at each study visit, the median serum phosphate levels one-hour post-dose 
were significantly lower than pre-dose values (1-12%; p≤0.04) (Figure 4). 
It should be noted, that one of the study participants was on a phosphate binder medication 
(sevelamer carbonate) at the start of the trial and therefore was not included in any of the serum 
phosphate analyses. Additionally, one subject who had hypercalcemic serum levels before any 
study drug administration was excluded from the day 1 serum ACa and phosphate analysis.  
Urinary calcium levels 
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Mean (±SD) 24-hour urinary calcium excretion was 189.8 (±131.6) mg pre-treatment, 192.3 
(±146.0) mg at the middle (end of week 8), and 140.5 (±82.4) mg at the end of the study (end of 
week 16). A non-significant change from baseline mean 24-hour urinary calcium was observed 
over the 16-week treatment period (26% p=0.07). 80% of the subjects had a decrease in urinary 
calcium levels by the end of the study. There were seven subjects who began the trial with 
calcium levels  above the 24-hr urinary calcium reference range (>200 mg for females; >250 mg 
for males). These subjects had a mean decrease of 21% in comparison to their baseline levels. 
Notably, six of the seven subjects had a decrease in 24-hr urinary calcium levels, three of which 
decreased to reference range levels.  
Safety 
During the 120-day study period, 18 of the 19 patients had at least one adverse event. A total of 
199 AEs were reported. The vast majority of AEs (195/199, 98.0%) were deemed unrelated to 
the study drug. The four AEs considered drug-related (mild nausea, moderate back pain, 
moderate headache and moderate upper abdominal pain) were reported by a single subject who 
withdrew consent on Day 1 after expressing fear of participating in the study. These AEs are 
unlikely related but, as this could not be confirmed by repeated dosing, they were recorded as 
‘possibly related’. Aside from the one patient that was withdrawn from the study due to 
hypercalcemia on Day 1 prior to receiving the first dose of the study, there were no other 
incidences of hypercalcemia adverse events, and no patient had serum ACa greater than 9.42 
mg/dL over the course of the treatment period. The most commonly observed adverse events 
were gastrointestinal disorders, including abdominal pain, nausea, and diarrhea (reported by 
37%, 32% and 26% of the patients, respectively), nasopharyngitis (32%) and muscle spasms 
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(26%). There were no clinically significant changes in blood chemistry and hematology 
measurements, physical findings, vital signs or ECG measurements. 
Quality of life 
QoL dimensions assessed using the VAS score of this instrument found generally good QOL at 
study start (80 (60 – 100); median (range); maximum score of 100) which increased at the first 
week of treatment. This improvement was maintained throughout the study, with a final QoL 
VAS score of 85 (60 – 100) (p=0.03) at week 16.  
Hypocalcemia-related symptoms 
Hypocalcemia-related symptoms were monitored throughout the study, starting from the end of 
week 1, and the total number of hypocalcemia-related symptoms/signs reported, decreased from 
a total of 13 (paresthesias, muscle cramps, emotional instability, anxiety, muscle weakness, and 
Chvostek sign) in 5 patients at the end of week 1 to 4 (paresthesias, anxiety, and hypotension) 
observed in 4 patients at the end of the study.  
Compliance with Study Medication 
All 17 subjects completing the study showed good compliance (>80%). One subject showed 
‘Satisfactory – Poor’ (<80%) compliance up until week 5, but his compliance improved to 
‘Good’ thereafter. The average compliance per subject for the entire study duration was 95.6% ± 
4.7% (mean ± SD). 
 DISCUSSION 
The treatment objective of hypoparathyroidism is to increase serum calcium to within 0.5 mg/dL 
of the lower limit of the reference range, but not into the reference range to reduce the risk of 
nephrolithiasis and ectopic calcification including nephrocalcinosis. (27) The standard therapy of 
HypoPT with oral calcium supplements and calcitriol analogs increases serum calcium but is 
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limited since it does not increase renal tubular calcium reabsorption or increase phosphate 
excretion. Hormonal replacement therapy with both hPTH(1-34) and PTH(1-84) have shown that 
this objective can be attained and that calcium homeostasis can be maintained at a steady level 
by PTH without hypercalciuria and at the same time reducing supplemental calcium requirements 
and improving quality of life of patients (9) (30-32) . The main differences between the commercial 
formulations of hPTH(1-34) and PTH(1-84) is the longer elimination half-life and longer time to 
peak concentration for the full-length molecule resulting in a longer pharmacologic effect 
following a single subcutaneous injection (31,32). Both hPTH(1-34) (Forteo) and PTH(1-84) 
(Natpara®)  require parenteral administration  because oral delivery and absorption of hPTH(1-
34), and of polypeptides in general, is hindered by extensive proteolysis inside the 
gastrointestinal tract, limited absorption due to their molecular mass and their hydrophilic nature 
(33). The oral route of administration is the most common, safest  and convenient method of 
dispensing a drug (34). Thus, an oral preparation of hPTH(1-34) which is easy to administer and 
has the potential to provide hPTH(1-34) throughout the day without the need for multiple 
injections will likely have a major impact on compliance, adherence, therapeutic impact and 
quality of life for patients in need of this chronic treatment.  Entera Bio has developed an oral 
formulation of hPTH(1-34) based on a novel drug delivery technology that facilitates absorption 
of proteins, which has achieved biologically relevant plasma concentrations of the drug (23). In 
order to obtain similar systemic exposure, the dose of Oral hPTH(1-34) administered in this 
study is significantly higher than the dose of commercially available subcutaneous PTH due to 
the lower absolute bioavailability of the oral formulation. 
This study demonstrated the safety and tolerability of Oral hPTH(1-34) administered four times 
daily for 16-weeks to patients with HypoPT. Treatment was associated with decreases in serum 
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phosphate, while serum ACa levels remained stable throughout the study. No drug-related 
serious adverse events were reported and most of the adverse events were not considered study 
drug-related. Oral hPTH(1-34) adjunct to conventional HypoPT treatment with supplemental 
calcium and alfacalcidol led to a statistically significant decrease in supplemental calcium 
requirements from week 4 until the end of the 16-week treatment period (42% p=0.001). In 40% 
of the patients, a 50% or more reduction from baseline calcium intake was achieved and in 73% 
of patients, the reduction was at least 30%. The four-week delay in reduction of calcium 
requirements was expected, as the study was designed with a gradual titration of the study drug 
dose. Supplemental calcium dose was significantly reduced while total serum ACa levels 
remained stable during the study. 
In contrast to the significant reduction in calcium requirements, the average calcitriol analog 
(alfacalcidol) doses did not change significantly. These results can be attributed to the study 
design, that targeted reduction of supplemental calcium, and its short duration. According to the 
study protocol, dose adjustments in calcitriol analogs were only to be implemented after reaching 
an adequate reduction of calcium supplement intake.  
The pharmacokinetic profile of the 0.75 mg dose of Oral hPTH(1-34) measured on the first 
treatment day was characterized by rapid absorption and elimination (Table 5). The overnight 
fast preceding the first dose may explain the slightly higher hPTH(1-34) absorption as compared 
to the second dose, which was administered three hours after a standard meal (Table 5). 
Following both the first and second dose, median plasma hPTH(1-34) concentrations (on a molar 
basis) reached the normal levels of endogenous hPTH(1-84) (adjusting for relative molecular 
weight). The main reason for the different pharmacokinetic profiles of the Oral hPTH(1-34) and 
injectable hPTH(1-84) is the prolonged release from the injection site of the latter, which results 
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in the significantly longer apparent plasma half-life (21.1- 27.5 min versus ~3h, respectively) (25) 
(34) . 
Following the first 0.75 mg Oral hPTH(1-34) dose on the first study day no significant effect was 
observed for serum ACa levels (Figure 2), while serum phosphate levels decreased to below the 
upper limit of the reference range approximately one hour after dosing (Figure 3). The 
pharmacodynamic effect on phosphate levels following administration of the first two study 
doses lasted at least 7 hours. Because of the limited number of blood sampling time points during 
the first study day, and not repeating measurements after the doses increased from 0.75 mg to 
2.25 mg later in the study, the complete pharmacokinetic and pharmacodynamic profile of the 
novel oral formulation of hPTH(1-34) was not obtained and additional investigation of the drug’s 
pharmacodynamics is required.  
In addition, similar to the pharmacodynamic profile shown on the first study day, at each of the 
subsequent study visits, serum phosphate levels rapidly decreased to within the reference range 
one hour after dosing. The median baseline serum phosphate levels measured at each treatment 
visit were consistently lower than the baseline levels at the study initiation.  
Mean urinary calcium levels decreased over the 16-week period of the study by 26%; this change 
was gradual and most prominent in the final 8 weeks of treatment. This decrease paralleled the 
gradual increase in the Oral hPTH(1-34) dose (near the maximum of 9 mg in all subjects by 
week 9) and the decrease in median supplemental calcium dose (from 3.6 g at week 1 to 2.4 g at 
week 8 to 2.2 g at week 16). Further studies with multiple timed serum and urine calcium 
evaluations in a controlled clinical setting would be required to determine the contribution of 
Oral hPTH(1-34) and supplemental calcium to urinary calcium excretion.  
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A small but statistically significant increase from baseline in quality of life was reported by 
patients. The limited increase may be attributed to both the relatively high QoL VAS score at the 
start of the study and the questionnaire used which did not address the specific symptoms of 
HypoPT. Additionally, the number of patients with symptoms related to hypocalcemia (such as 
paresthesias, muscle cramps, emotional eating, instability, anxiety, and fatigue) appeared to 
decrease by the end of the study (13 patients at week 1 versus 4 patients by the end of week 16). 
Significant limitations of the study included the small sample size and the short duration of the 
study. As it was a pilot study, it did not include blinded concurrent treatment with placebo, and 
there was no run-in period in which standard treatment with supplemental calcium and calcitriol 
analogs was optimized according to a protocol prior to the start of Oral hPTH(1-34). Other study 
limitations were the limited pharmacodynamic time points on the first day of the study, and the 
at-home urine collections as opposed to collection in a controlled clinical setting. Additionally, 
because there was no placebo control group, quality of life results and reported hypocalcemia 
symptoms should be interpreted with caution, as the placebo effect may have contributed to the 
study outcome. Despite these limitations, the study findings of the Oral hPTH(1-34) effect on 
serum ACa and phosphate levels, which enabled statistically significant reductions in oral 
calcium requirements, were clinically significant. 
An additional drawback of the study was the high number of tablets patients were required to 
take - up to three tablets taken four times a day, as at the time of the study, the tablets were only 
available at a single strength. It should be noted, however, that the tablets administered in the 
study were significantly smaller in size than the calcium supplements that these patients are 
accustomed to taking regularly (~130 mg vs ~1500 mg). Additionally, there were no compliance 
issues related to the number of tablets or dose administered.  
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In conclusion, this study is the first to report on the use of an oral hPTH(1–34) formulation in the 
treatment of patients with HypoPT as part of Entera Bio’s EB612 development program. As an 
add–on therapy in this patient population, Oral hPTH(1-34) achieved significant systemic 
exposure, exhibited a promising pharmacodynamic profile, was generally safe and well tolerated 
and was effective in reducing calcium supplement requirements. Further long-term, placebo-
controlled studies are necessary to confirm the reported findings and to assess whether Oral 
hPTH(1-34) can serve as a new therapy for the treatment of HypoPT. 
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Table 1: Recommended changes to calcium (Ca) supplements and alfacalcidol or hPTH(1-34) 
dosages in accordance with patient’s albumin adjusted serum Ca (ACa) 
ACa (mg/dL) Recommended Action  
< 8  
Increase hPTH(1-34) dose by 2 tablets daily. Increase Ca 
supplements/alfacalcidol, appropriately.* 
8 - 8.6  
Increase hPTH(1-34) dose by 1 tablet daily. Maintain Ca supplements and 
alfacalcidol doses. 
8.6 - 9.2  Decrease Ca supplements by 500 mg daily.  
9.2 - 9.8  
Decrease Ca supplements by 500mg daily or – if not receiving calcium – 
decrease alfacalcidol appropriately.* 
9.8 - 10.4  
Decrease Ca supplements by 500-1000mg daily or – if not receiving calcium 
– decrease alfacalcidol supplementation appropriately.*  
If not on Ca or alfacalcidol, reduce hPTH(1-34) by a single tablet. 
> 10.4  
Decrease as for 9.6 -10.4 mg/dl and may require stopping hPTH(1-34) 
therapy transiently until values return to normal. 
Albumin-adjusted Calcium (ACa) calculated as Serum Calcium (total) + [0.8 x (4.0-serum 
albumin)] 
Table 2: Baseline demographics and clinical parameters 
Characteristic Study Population 
(N= 19) 
Gender, n (%) 
 Male 3 (15.8) 
23 
 
 Female 16 (84.2) 
Age, mean ± SD (years) 44.6 ± 16.1 
Weight, mean ± SD (kg) 73.6 ± 17.3 
BMI, mean ± SD (kg/cm2) 26.6 ± 4.4 
BMI, median (range), (kg/cm2) 25.5 (19.8 – 33.8) 
Etiology HypoPT, n (%)  
 Acquired  13 (68.4) 
 Autoimmune 5 (26.3) 
 Hereditary 1 (5.3) 
Supplemental calcium dose, mean ± SD (range), (g/d)a 3.7±2.4 (1.2-10.8) 
Alfacalcidol dose, mean ± SD (range), (µg/d) a 1.1±0.7 (0.25-2) 
Serum ACa, mean ± SD (mg/dL)a, b 8.0±0.57 
Serum phosphate, mean ± SD (mg/dL)a (range) 5.0±0.84 (3.7-7.0) 
a N=15 (patients completed the study per protocol) 
b Target ACa levels for HypoPT patients are >7.5 mg/dL 
 
SD= standard deviation, HypoPT= Primary Hypoparathyroidism, ACa – Albumin-adjusted Serum 
Calcium 
Table 3: Average daily dose of hPTH(1-34) acetate during each week over the course of the 16-
week treatment period  
 Mean (mg) SD Range (mg) 
Week 1 3.0 0.0 (3.0 – 3.0) 
Week 2 4.9 1.4 (3.0 – 6.0) 
Week 3 7.2 2.5 (3.0 – 9.0) 
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Week 4 7.4 2.2 (3.8 - 9.0) 
Week 5 7.4 2.2 (3.0 - 9.0) 
Week 7 8.2 1.7 (3.0 - 9.0) 
Week 9 8.7 0.6 (7.5 - 9.0) 
Week 11 9.0 0.0 (9.0 - 9.0) 
Week 13 9.0 0.0 (9.0 - 9.0) 
Week 16 9.0 0.0 (9.0 - 9.0) 
N=15    
Table 4: Summary of daily supplemental calcium dose (± SD) during each week over the course 
of the 16-week treatment period. 
 Mean (g) SD (g) Median (g) 
Week 1 3.7 2.4 3.6 
Week 2 3.6 2.4 3.3 
Week 3 3.4 2.4 3.0 
Week 4 3.0 2.1 3.0 
Week 5 3.0 2.1 2.4 
Week 6 2.9 2.1 2.4 
Week 7 2.8 2.1 2.4 
Week 8 2.7 2.2 2.4 
Week 9 2.6 2.1 2.4 
Week 10 2.5 2.1 2.4 
Week 11 2.4 2.1 2.4 
Week 12 2.4 2.1 2.4 
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Week 13 2.4 2.1 2.4 
Week 14 2.4 2.1 2.4 
Week 15 2.4 2.1 2.4 
Week 16 2.3 2.1 2.2 
N=15 
Table 5: Main pharmacokinetic parameters measured for the first two doses of Oral hPTH(1-34) 






Cmax median (range), (pg/mL) 47.9 (14.5 - 427.2) 41.2 (5.6 - 213.4) 
Tmax median (range), (minutes) 20.0 (10.0 - 45.0) 30.0 (10.0 - 90.0) 
AUClast median (range), (pg/L*hours) 70.9 (7.6 – 638.9) 52.6 (2.4 – 746.8) 










Figure 1. Change from baseline daily calcium supplement requirements and serum ACa 
levels. A. Box plot represents the percent of baseline supplemental calcium doses for subjects 
(N=15) treated with Oral hPTH(1-34) at the beginning of each treatment week (16 weeks). Bold 
line represents the median values. Whiskers represent the minimum and maximum values. At 
weeks 4-16, the percent change from baseline supplemental calcium doses was statistically 
significant (p ≤ 0.006). P values for percent change from baseline for each visit were calculated 
using Wilcoxon signed-rank test. B. Box plot represents serum ACa levels (N=15) at each study 
visit (the last of which occurred at the beginning of week 17). Bold line represents the median 
values. Whiskers represent the minimum and maximum values.  
Figure 2. Median and Individual Serum Albumin adjusted Calcium (ACa) and Mean 
hPTH(1-34) levels following each of the first two doses of Oral hPTH(1-34). Following the 
first and second dose of 0.75 mg hPTH(1-34) on Day 1, in the clinic, blood samples were 
collected at predetermined intervals for hPTH(1-34) and ACa analysis. The median (bold line) 
ACa profile (N=18) is superimposed on the geometric mean (dashed line) drug pharmacokinetic 
profile (N=19). See Table 5 for complete pharmacokinetic data analysis. One subject was 
omitted from the ACa analysis due to their pre-dose hypercalcemic levels.  
Figure 3. Median and Individual Phosphate and Mean hPTH(1-34) levels following each of 
the first two doses of Oral hPTH(1-34). hPTH(1-34). Following the first and second dose of 
0.75 mg hPTH(1-34) on Day 1, in the clinic, blood samples were collected at predetermined 
intervals for hPTH(1-34) and serum phosphate analysis. The median (bold line) phosphate 
profile (N=17) is superimposed on the geometric mean (dashed line) drug pharmacokinetic 
profile (N=19).  See Table 5 for complete pharmacokinetic data analysis.  Two subjects were 
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omitted from the serum phosphate analysis, one due to pre-dose hypercalcemic levels and the 
second was on a phosphate binder medication. The grey dashed line represents the upper level of 
the reference range for serum phosphate in adults (4.5 mg/dL). 
Figure 4. Serum phosphate levels following Oral hPTH(1-34) administration. At each 
treatment visit over the 16-week treatment period, blood sampling for serum phosphate analysis 
was performed before and 1-hour after Oral hPTH(1-34) administration. Box plot represents the 
serum phosphate levels at T=0 and T=60 minutes post-dose at each study visit (the last of which 
occurred at the beginning of week 17). Whiskers represent the minimum and maximum values. 
The grey dashed line represents the upper level of the reference range for serum phosphate in 
adults (4.5 mg/dL). The bold line shows the change in median phosphate levels from T=0 to 
T=60 per visit. p ≤ 0.04 when comparing pre-dose to one-hour post-dose values at each study 
visit. P values were calculated using t test for paired samples. 
 
 
 
 
